Table 1 Standard of care treatment and sustained virological response rates for chronic hepatitis C patients
From: Treatment of hepatitis C virus infection in the future
References | G | Number of patients | Naïve or re-treatment | Formula of therapy | Duration of treatment (weeks) | SVR rates (%) | Notes |
|---|---|---|---|---|---|---|---|
[24] | G1 | 298 | Â | Peginterferon alfa-2a plus ribavirin | 48 | 46 | Â |
285 | Â | Interferon alfa-2b plus ribavirin | 48 | 36 | Â | ||
145 | Â | Peginterferon alfa-2a plus placebo | 48 | 21 | Â | ||
[24] | G2/G3 | 140 | Â | Peginterferon alfa-2a plus ribavirin | 48 | 76 | Â |
145 | Â | Interferon alfa-2b plus ribavirin | 48 | 61 | Â | ||
69 | Â | Peginterferon alfa-2a plus placebo | 48 | 45 | Â | ||
[24] | G4 | 13 | Â | Peginterferon alfa-2a plus ribavirin | 48 | 77 | Â |
11 | Â | Interferon alfa-2b plus ribavirin | 48 | 36 | Â | ||
9 | Â | Peginterferon alfa-2a plus placebo | 48 | 22 | Â | ||
[25] | G1 (98%) | 100 | Â | Peginterferon alfa-2b plus placebo | 48 | 19 | Blacks |
100 | Â | Peginterferon alfa-2a plus ribavirin | 48 | 52 | Non-Hispanic Whites | ||
[26] | G2/3 | 732 | Â | Peginterferon alfa-2a plus ribavirin | 16 | 65 | Â |
731 | Â | Peginterferon alfa-2a plus ribavirin | 24 | 76 | Â | ||
[27] | G1 | 269 | naive | Peginterferon alfa-2a plus ribavirin | 48 | 34 | Latino |
300 | naive | Peginterferon alfa-2a plus ribavirin | 48 | 49 | Non-Latino |